Starting January 15, 2016, customers with Cigna pharmacy coverage will need to try Repatha (evolocumab) for treatment of a high cholesterol condition known as homozygous familial hypercholesterloemia (HoFH) before Juxtapid or Kynamro will be covered.

Physicians with patients who are currently approved by Cigna for coverage of Juxtapid or Kynamro to treat HoFH can either switch their patients to Repatha immediately or have them continue to take the drug until the approval period ends.

If for medical reasons the prescribing physician feels Repatha isn't right for their patient and wants him or her to continue to take Juxtapid or Kynamro, the physician will need to submit a precertification request and have it approved by Cigna.